로딩 중…
지수 로딩 중…
Lunit Inc.
328130· KOSDAQ· Health Care· Health Care Equipment & Services
₩9,880-7.14%
2026-06-26
Price Chart
Lunit Inc.-59.23%
Financials
Investment Metrics(as of 2026-06-26)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 735.65B KRW |
| Revenue | 87.88B KRW |
| Net Income | -67.23B KRW |
| Total Assets | 389.65B KRW |
| Net Assets | 124.74B KRW |
| Employees | 320 |
| Value | |
| P/B | 5.90x |
| P/S | 8.37x |
| FCF Yield | -7.59% |
| Profitability | |
| ROE | -53.89% |
| ROA | -17.25% |
| Op. Margin | -86.52% |
| Revenue Growth | 24.74% |
| Earnings Growth | -978.49% |
| Financial Health | |
| Debt Ratio | 212.37% |
| Total Debt | 130.28B KRW |
| FCF | -55.81B KRW |
| Cash | 38.80B KRW |
| Current Ratio | 0.32x |
| Performance | |
| 1Y Return | -59.23% |
| 1M Return | -42.49% |
| From 52W High | -65.27% |
| 1Y MDD | -63.41% |
| Trading | |
| Volume | 709,952 shares |
| Foreign Own. | 12.03% |
| Per Share | |
| EPS | -1,074 KRW |
| BPS | 1,992 KRW |
Company Info
Lunit, established in 2013 and headquartered in Gangnam-gu, Seoul, is a deep learning-based medical artificial intelligence enterprise that entered the U.S. market in 2024 through the acquisition of Volpara. The company develops cancer diagnostic image interpretation solution Lunit INSIGHT and biomarker solution Lunit SCOPE, offering product lines for cancer detection and treatment in chest X-rays and mammography. Lunit also expands its research and development and launches DBT products through partnerships with global manufacturers such as GE Healthcare.